About this Journal Submit a Manuscript Table of Contents
Journal of Blood Transfusion
Volume 2012 (2012), Article ID 407326, 6 pages
http://dx.doi.org/10.1155/2012/407326
Review Article

Using Basic Ethical Principles to Evaluate Safety Efforts in Transfusion Medicine

Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, P.O. Box 100275, Gainesville, FL 32610-0275, USA

Received 10 October 2011; Accepted 22 November 2011

Academic Editor: Peter J. M. van den Burg

Copyright © 2012 Jay P. Brooks. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Cambridge Dictionaries Online, “Zero-sum game,” October 2011, http://dictionary.cambridge.org/dictionary/business-english/zero-sum-game.
  2. “Inpatient Reimbursement May Improve for Blood and Blood Components for Transfusion,” Blood Counts; Blood Centers of the Pacific - Update, October 2011, http://www.bloodcenters.org/docs/hu_may_2002.pdf.
  3. “Blood services: costs, reimbursement and billing. Blood Counts,” ABC Publications, September 2005, http://www.americasblood.org/download/bloodcounts_v4_n1.pdf.
  4. R. S. Shilts, And the Band Played On, St. Martin’s Press, New York, NY, USA, 1st edition, 1987.
  5. M. P. Busch, M. J. Young, S. M. Samson, J. W. Mosley, J. W. Ward, and H. A. Perkins, “Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening,” Transfusion, vol. 31, no. 1, pp. 4–11, 1991.
  6. L. T. Goodnough, M. E. Brecher, M. H. Kanter, and J. P. Aubuchon, “Medical progress: transfusion medicine (Second of two parts)—blood conservation,” New England Journal of Medicine, vol. 340, no. 7, pp. 525–533, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. P. AuBuchon, J. D. Birkmeyer, and M. P. Busch, “Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood,” Transfusion, vol. 37, no. 1, pp. 45–51, 1997. View at Scopus
  8. D. A. Marshall, S. H. Kleinman, J. B. Wong et al., “Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States,” Vox Sanguinis, vol. 86, no. 1, pp. 28–40, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. T. A. Ratko, J. P. Cummings, H. A. Oberman et al., “Evidence-based recommendations for the use of WBC-reduced cellular blood components,” Transfusion, vol. 41, no. 10, pp. 1310–1319, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. J. D. Sweeney, “Universal leukoreduction of cellular blood components in 2001?” American Journal of Clinical Pathology, vol. 115, no. 5, pp. 666–673, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. L. T. Goodnough, “Universal leukoreduction of cellular blood components in 2001?” American Journal of Clinical Pathology, vol. 115, no. 5, pp. 674–677, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. E. C. Vamvakas and M. A. Blajchman, “Universal WBC reduction: the case for and against,” Transfusion, vol. 41, no. 5, pp. 691–712, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. W. H. Dzik, “Leukoreduction of blood components,” Current Opinion in Hematology, vol. 9, no. 6, pp. 521–526, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. “BPAC recommends universal leukoreduction,” AABB Newsbriefs, vol. 20, article 16, 1998.
  15. “Revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob Disease (CJD) and variant Creutzfeldt-Jakob Disease (vCJD) by blood and blood products,” Guidance for Industry, January 2002, http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm079711.pdf.
  16. “Questions and answers on FDA Guidance entitled “Revised Preventative Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob (CJD) Disease and Variant Creutzfeldt -Jakob Disease (VCJD) by Blood and Blood Products,” Guidance for Industry, January 2004, http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm074100.htm.
  17. “Draft compliance policy guidance for FDA staff and industry (not for implementation),” chapter - 2 sub chapter - 230 Sec. 230.150 blood donor incentives, October 2011, http://www.fda.gov/OHRMS/DOCKETS/98fr/001679gd.pdf.
  18. “Red Cross to hold raffle for Rolling Stones tickets,” 2011, http://www.gazettetimes.com/news/local/article_f06755c8-7366-57ca-8441-06f71f644b60.html.
  19. “Save the Date – Quincy 12 hours of giving,” 2011, http://www.redcrossblood.org/news/heartofamerica/save-date-quincy-12-hours-giving.
  20. “Mustang give away announced! Classic 1966 Mustang coupe given away September 18,” 2011, http://beta.catt.com/article.php?story=20040809111741281.
  21. “Red Cross Kenneth L. Mitchell Detroit Donor Center hosts special community event, offers opportunity to help save lives & win Saturn Ion. U. S. Newswire,” 2011, http://www.highbeam.com/doc/1P2-13201771.html.
  22. J. P. Brooks, “The rights of blood recipients should supersede any asserted rights of blood donors,” Vox Sanguinis, vol. 87, no. 4, pp. 280–286, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. P. Tatchell, “Gay blood ban is homophobic,” 1996, http://www.petertatchell.net/lgbt_rights/blood_ban/blood_ban_on_gays_is_homophobic.htm.
  24. B. Jennelle, “Bleeding for a change. The Harvard Crimson Online,” 2002, http://www.thecrimson.com/article.aspx?ref=255627.
  25. E. Garza, “Blood shortages lead some to question ban on gay donors. The Daily Texan,” 2001, http://www.highbeam.com/doc/1P1-45896722.html.
  26. “Students at Oregon university cancel blood drive to protest policy on gays,” Associated Press, 2003, http://www.ap.org.
  27. “McGill student group bans blood drives over questionnaire,” CBC News, 2006, http://www.cbc.ca/montreal/story/print/qc_20041803.
  28. B. Publicover, “York University bans blood donor clinic. The Peak,” 1998, http://www.peak.sfu.ca/the-peak/98-3/issue7/blood.html.
  29. Z. R. Heineman, “BOND members urged to participate in blood drive. The Harvard Crimson Online,” 2001, http://www.thecrimson.com/article.aspx?ref=120959.
  30. “Blood Products Advisory Committee 67th meeting [monograph on the Internet],” Rockville (MD): U.S. Food and Drug Administration, 2001http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3649t1.rtf.
  31. K. Soldan and K. Sinka, “Evaluation of the de-selection of men who have had sex with men from blood donation in England,” Vox Sanguinis, vol. 84, no. 4, pp. 265–273, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Germain, R. S. Remis, and G. Delage, “The risks and benefits of accepting men who have had sex with men as blood donors,” Transfusion, vol. 43, no. 1, pp. 25–33, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Spencer, J. Rios, and R. Cable, “Marginal recruitment impact of potential alterations to FDA deferral criteria for men who have sex with men [1],” Transfusion, vol. 46, no. 5, pp. 869–870, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. “Statement of the American Association of Blood Banks before the Blood Products Advisory Committee: donor deferral policy regarding men who have had sex with another man even one time since 1977,” September 2000.
  35. S Kleinman, “Behavior-based blood donors deferrals in the era of nucleic acid testing (NAT). Statement before the Blood Products Advisory Committee,” ABC Statements 2006, http://www.americasblood.org/download/releases/stmnt_060309_deferrals-msm.pdf.
  36. W. H. Dzik, “Emily Cooley Lecture 2002: transfusion safety in the hospital,” Transfusion, vol. 43, no. 9, pp. 1190–1199, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. J. P. Brooks, “Reengineering transfusion and cellular therapy processes hospitalwide: ensuring the safe utilization of blood products,” Transfusion, vol. 45, no. 4, pp. 159S–171S, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. R. Koshy, “Navigating the information technology highway: computer solutions to reduce errors and enhance patient safety,” Transfusion, vol. 45, no. 4, pp. 189S–205S, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. J. P. AuBuchon and B. Littenberg, “A cost-effectiveness analysis of the use of a mechanical barrier system to reduce the risk of mistransfusion,” Transfusion, vol. 36, no. 3, pp. 222–226, 1996. View at Scopus
  40. L. M. Schwartz, S. Woloshin, W. C. Black, and H. G. Welch, “The role of numeracy in understanding the benefit of screening mammography,” Annals of Internal Medicine, vol. 127, no. 11, pp. 966–972, 1997. View at Scopus
  41. M. V. Williams, R. M. Parker, D. W. Baker et al., “Inadequate functional health literacy among patients at two public hospitals,” Journal of the American Medical Association, vol. 274, no. 21, pp. 1677–1682, 1995. View at Scopus
  42. J. A. Gazmararian, D. W. Baker, M. V. Williams et al., “Health literacy among medicare enrollees in a managed care organization,” Journal of the American Medical Association, vol. 281, no. 6, pp. 545–551, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Katz, “Syphilis testing - statement of the American Association of Blood Banks before the Blood Products Advisory Committee,” 2000, http://www.aabb.org/pressroom/statements/Pages/bpacsyph091400.aspx.
  44. C. Goodman, S. Chan, P. Collins, R. Haught, and Y. J. Chen, “Ensuring blood safety and availability in the US: Technological advances, costs, and challenges to payment—final report,” Transfusion, vol. 43, no. 8, pp. 3S–46S, 2003. View at Scopus
  45. FDA, “Use of nucleic acid tests on pooled and individual samples from donations of whole blood and blood components (including source plasma and source leukocytes) to adequately and appropriately reduce the risk of transmission of HIV-1 and HCV – Guidance for Industry,” 2004, http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm080291.pdf.
  46. C. Bianco, “Actions to promote global safety and availability throughout the world. ABC Publications,” 2001, http://www.hhs.gov/ash/bloodsafety/advisorycommittee/pastmeetings/transcripts/20010419.html.
  47. J. Leach Bennett, M. A. Blajchman, G. Delage, M. Fearon, and D. Devine, “Proceedings of a consensus conference: risk-based decision making for blood safety,” Transfusion Medicine Reviews, vol. 25, no. 4, pp. 267–292, 2011. View at Publisher · View at Google Scholar · View at PubMed